Due to the rapid degradation of native GLP-1 by dipeptidyl peptidase-4 (DPP-4), resulting in a short half-life, GLP-1 receptor agonists (GLP-1RAs) have been developed to provide a more effective and sustained therapeutic option for diabetes management [107]. Here, DPP4 is linked to diabetes mellitus.